Effect Of Maraviroc On The Pharmacokinetics Of Digoxin

This study has been completed.
Information provided by:
ViiV Healthcare
ClinicalTrials.gov Identifier:
First received: January 22, 2010
Last updated: April 6, 2011
Last verified: April 2011
This is an open labelled study to estimate the effect of maraviroc on the pharmacokinetics of digoxin, a probe for p-glycoprotein.

Condition Intervention Phase
HIV Infections
Drug: Digoxin
Drug: Maraviroc
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Open-Label, Fixed Sequence, Crossover Study To Estimate The Effect Of Multiple Dose Maraviroc On Single Dose Digoxin Pharmacokinetics In Healthy Subjects

Resource links provided by NLM:

Further study details as provided by ViiV Healthcare:

Primary Outcome Measures:
  • To estimate the effect of multiple dose maraviroc on the pharmacokinetics of digoxin. [ Time Frame: 21 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To investigate the safety and tolerability of maraviroc and digoxin when co-administered. [ Time Frame: 21 days ] [ Designated as safety issue: Yes ]

Enrollment: 12
Study Start Date: March 2010
Study Completion Date: April 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Digoxin Drug: Digoxin
Oral Digoxin 0.25 mg single dose
Experimental: Digoxin + Maraviroc Drug: Digoxin
Oral Digoxin 0.25 mg single dose on Day 5
Drug: Maraviroc
Oral Maraviroc 300 mg twice daily for 6 days
Other Name: Selzentry, Celsentri


Ages Eligible for Study:   21 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy male and/or female subjects between the ages of 21 and 55 years, inclusive.
  • Body Mass Index (BMI) of 17.5 to 25.5 kg/m2.
  • Total body weight >50 kg (110 lbs).

Exclusion Criteria:

  • Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication.
  • Subjects with an estimated creatinine clearance (CLcr) <80 ml/min.
  • Pregnant or nursing females.
  • Females of childbearing potential who are unwilling or unable to use an acceptable method of contraception as outlined in this protocol from at least 14 days prior to the first dose of study medication until completion of study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01056874

Pfizer Investigational Site
Singapore, Singapore, 188770
Sponsors and Collaborators
ViiV Healthcare
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc.
ClinicalTrials.gov Identifier: NCT01056874     History of Changes
Other Study ID Numbers: A4001097 
Study First Received: January 22, 2010
Last Updated: April 6, 2011
Health Authority: China: Centre for Pharmaceutical Administration Health Sciences Authority Singapore

Keywords provided by ViiV Healthcare:
Drug Interaction

Additional relevant MeSH terms:
Anti-Arrhythmia Agents
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antiviral Agents
CCR5 Receptor Antagonists
Cardiotonic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Protective Agents

ClinicalTrials.gov processed this record on May 25, 2016